ArticleThe Journal of investigative dermatology2015

Omalizumab, an Anti-IgE mAb, receives approval for the treatment of chronic idiopathic/spontaneous urticaria.

Keith C P Wu et al.PubMed ↗Publisher ↗

No numbers read from the abstract.